Screener
Design Therapeutics, Inc. DSGN Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Design Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026.
- Filed
- Apr 28, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-187063
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from financing activities | ||
| Proceeds from the issuance of common stock in at-the-market offering, net of issuance costs | 19,907 | — |
| Proceeds from the exercise of stock options | 27 | 23 |
| Net cash provided by financing activities | 19,934 | 23 |
| Net decrease in cash and cash equivalents | (4,086) | (8,896) |
| Cash and cash equivalents at beginning of period | 16,856 | 22,563 |
| Cash and cash equivalents at end of period | $12,770 | $13,667 |
| Supplemental disclosures |
Item 1. Financial Statements.
FAQ
- What is Design Therapeutics, Inc.'s financing cash flow?
- Design Therapeutics, Inc. (DSGN) reported financing cash flow of $19.93M in Q1 2026.
- How has Design Therapeutics, Inc.'s financing cash flow changed year-over-year?
- Design Therapeutics, Inc.'s financing cash flow increased by 86569.6% year-over-year, from $23K to $19.93M.
- What is the long-term trend for Design Therapeutics, Inc.'s financing cash flow?
- Over 3 years (2021 to 2025), Design Therapeutics, Inc.'s financing cash flow has grown at a -59.2% compound annual growth rate (CAGR), from $379.21M to $25.74M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Design Therapeutics, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude